Division of Neurology, Nephrology and Rheumatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Nephron Exp Nephrol. 2012;122(1-2):23-35. doi: 10.1159/000346569. Epub 2013 Mar 14.
BACKGROUND/AIMS: Matrix metalloproteinases (MMPs) are zinc endopeptidases that degrade extracellular matrix and are involved in the pathogenesis of ischemic damage in acute kidney injury (AKI). In the present study, we analyzed the role of MMP-2 in the repair process in ischemic AKI.
AKI was induced in MMP-2 wild-type (MMP-2(+/+)) and MMP-2-deficient (MMP-2(-/-)) mice by 90-min renal artery clamping followed by reperfusion. Renal histology and the activity and distribution of MMP-2 were examined from day 1 to day 14. During the recovery from AKI, MMP-2(+/+) mice were also treated with MMP-2/MMP-9 inhibitor.
In both MMP-2(+/+) and MMP-2(-/-) mice, AKI developed on day 1 after ischemia/reperfusion with widespread acute tubular injury, but subsequent epithelial cell proliferation was evident on days 3-7. During the repair process, active MMP-2 and MMP-9 increased in regenerating tubular epithelial cells in MMP-2(+/+) mice on days 7-14, and the tubular repair process was almost complete by day 14. On the other hand, in MMP-2(-/-) mice, less prominent proliferation of tubular epithelial cells was evident on days 3 and 7, and damaged tubules that were covered with elongated and immature regenerated epithelial cells were identified on days 7 and 14. Incomplete recovery of injured microvasculature was also noted with persistent macrophage infiltration. Similarly, treatment with MMP-2/MMP-9 inhibitor resulted in impaired recovery in MMP-2(+/+) mice.
MMP-2 is involved in tubular repair after AKI. The use of the MMP-2/MMP-9 inhibitor was a disadvantage when it was administered during the repair stage of ischemic AKI. Treatment with MMP inhibitor for AKI needs to be modified to enhance recovery from AKI.
背景/目的:基质金属蛋白酶(MMPs)是锌内肽酶,可降解细胞外基质,参与急性肾损伤(AKI)中缺血损伤的发病机制。在本研究中,我们分析了 MMP-2 在缺血性 AKI 修复过程中的作用。
通过 90 分钟的肾动脉夹闭再灌注,在 MMP-2 野生型(MMP-2(+/+))和 MMP-2 缺陷型(MMP-2(-/-))小鼠中诱导 AKI。从第 1 天到第 14 天,检查肾脏组织学以及 MMP-2 的活性和分布。在 AKI 恢复期,MMP-2(+/+)小鼠还接受了 MMP-2/MMP-9 抑制剂的治疗。
在 MMP-2(+/+)和 MMP-2(-/-)小鼠中,缺血再灌注后第 1 天均发生 AKI,表现为广泛的急性肾小管损伤,但随后在第 3-7 天可见上皮细胞增殖。在修复过程中,MMP-2(+/+)小鼠再生肾小管上皮细胞中的活性 MMP-2 和 MMP-9 在第 7-14 天增加,到第 14 天,管状修复过程几乎完成。另一方面,在 MMP-2(-/-)小鼠中,第 3 天和第 7 天可见上皮细胞增殖不明显,第 7 天和第 14 天可见受损的肾小管被伸长和不成熟的再生上皮细胞覆盖。受损微血管的恢复也不明显,伴有持续的巨噬细胞浸润。同样,MMP-2(+/+)小鼠中 MMP-2/MMP-9 抑制剂的治疗导致恢复受损。
MMP-2 参与 AKI 后的管状修复。在缺血性 AKI 的修复阶段使用 MMP-2/MMP-9 抑制剂是不利的。针对 AKI 的 MMP 抑制剂治疗需要进行修改,以增强 AKI 的恢复。